Sherri L Stewart1, Rhea Harewood2, Melissa Matz2, Sun Hee Rim1, Susan A Sabatino1, Kevin C Ward3, Hannah K Weir1. 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. 3. Rollins School of Public Health, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD-2 study, the largest and most geographically comprehensive, population-based survival study to date. METHODS: Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state-specific and race-specific life tables. RESULTS: Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one-half were diagnosed at distant stage. Five-year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001-2003 and 31.1% from 2004-2009), despite similar stage distributions. Stage-specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage. CONCLUSIONS: The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines-based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival. Cancer 2017;123:5138-59. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND:Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD-2 study, the largest and most geographically comprehensive, population-based survival study to date. METHODS: Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state-specific and race-specific life tables. RESULTS: Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one-half were diagnosed at distant stage. Five-year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001-2003 and 31.1% from 2004-2009), despite similar stage distributions. Stage-specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage. CONCLUSIONS: The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines-based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival. Cancer 2017;123:5138-59. Published 2017. This article is a U.S. Government work and is in the public domain in the USA. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Entities:
Keywords:
cancer registries; ovarian cancer; population-based survival; surveillance; survival
Authors: Jason D Wright; Ling Chen; Ana I Tergas; Sonali Patankar; William M Burke; June Y Hou; Alfred I Neugut; Cande V Ananth; Dawn L Hershman Journal: Obstet Gynecol Date: 2015-06 Impact factor: 7.661
Authors: Robert E Bristow; Jenny Chang; Argyrios Ziogas; Belinda Campos; Leo R Chavez; Hoda Anton-Culver Journal: J Am Coll Surg Date: 2015-02-14 Impact factor: 6.113
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs Journal: Lancet Oncol Date: 2009-03-11 Impact factor: 41.316
Authors: Phyllis A Wingo; Patricia M Jamison; Robert A Hiatt; Hannah K Weir; Paul M Gargiullo; Mary Hutton; Nancy C Lee; H Irene Hall Journal: Cancer Causes Control Date: 2003-03 Impact factor: 2.506
Authors: J K Chan; R Urban; M K Cheung; K Osann; J Y Shin; A Husain; N N Teng; D S Kapp; J S Berek; G S Leiserowitz Journal: Br J Cancer Date: 2006-10-31 Impact factor: 7.640
Authors: Claudia Allemani; Rhea Harewood; Christopher J Johnson; Helena Carreira; Devon Spika; Audrey Bonaventure; Kevin Ward; Hannah K Weir; Michel P Coleman Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Thomas B Richards; S Jane Henley; Mary C Puckett; Hannah K Weir; Bin Huang; Thomas C Tucker; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Holly R Harris; Kristin A Guertin; Tareq F Camacho; Courtney E Johnson; Anna H Wu; Patricia G Moorman; Evan Myers; Traci N Bethea; Elisa V Bandera; Charlotte E Joslin; Heather M Ochs-Balcom; Lauren C Peres; Will T Rosenow; Veronica W Setiawan; Alicia Beeghly-Fadiel; Lauren F Dempsey; Lynn Rosenberg; Joellen M Schildkraut Journal: Int J Cancer Date: 2022-06-30 Impact factor: 7.316
Authors: Lauren C Peres; Sweta Sinha; Mary K Townsend; Brooke L Fridley; Beth Y Karlan; Susan K Lutgendorf; Eileen Shinn; Anil K Sood; Shelley S Tworoger Journal: Gynecol Oncol Date: 2019-12-12 Impact factor: 5.482
Authors: Zhixin Wang; Sarah Dilley; HyounKyoung G Park; Alfred A Bartolucci; Chenguang Wang; Warner K Huh; Sejong Bae Journal: Cancer Health Disparities Date: 2019-08-19
Authors: Matthew Schlumbrecht; Danielle Cerbon; Melissa Castillo; Scott Jordan; Raleigh Butler; Andre Pinto; Sophia George Journal: Front Oncol Date: 2020-05-29 Impact factor: 6.244